叔丁胺氢溴酸盐 | 60469-70-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 叔丁胺氢溴酸盐
• 中文别名: 叔丁胺氢溴酸
• 英文名称: tert-butylammonium bromide
• 英文别名: t-butylammonium bromide；tert-butylamine hydrobromide；hydron;2-methylpropan-2-amine;bromide
• CAS: 60469-70-7
• 化学式: Br*C₄H₁₂N
• 分子量: 154.05
• InChiKey: CQKAPARXKPTKBK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.32
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

安全信息

• 海关编码：
  2923900090
• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  lead(II) bromide 、 叔丁胺氢溴酸盐 以 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  混合卤化物排序作为稳定 Ruddlesden-Popper 结构的工具

  摘要：

  虽然与三维钙钛矿相比，层状二维钙钛矿对有机阳离子选择的限制大大放松，但由于四个相邻角共享之间的无机袋的大小，间隔阳离子的形状仍然受到限制八面体。为了研究间隔阳离子支化对 Ruddlesden-Popper (RP) 结构形成的影响，我们对使用叔丁基铵 ( t -BA) 形成的结构进行了全面研究。我们证明，与纯溴化物和纯碘化物相比，使用混合卤化物能够形成t -BA 2 PbBr 2 I 2RP 钙钛矿结构，具有特定排序的溴化物和碘化物阴离子。t -BA 间隔物，尽管其支化和庞大的形状阻止其更深的穿透，但如果无机袋的设计方式使溴化物阴离子占据末端轴向位置，而碘化物占据赤道位置。我们通过层状钙钛矿的最小跳跃算法使用全局优化在实验确定和理论预测的结构之间获得了极好的一致性，说明了预测 RP 钙钛矿结构和通过合理设计无机口袋来操纵钙钛矿结构的能力。

  DOI：

  10.1021/acs.chemmater.1c03815
• 作为产物：
  描述：

  溴化氰 、 叔丁胺 以 乙醚 为溶剂， 反应 0.25h， 生成 叔丁胺氢溴酸盐
  参考文献：
  名称：

  A novel one-pot synthesis of hydroximoyl chlorides and 2-isoxazolines using N-tert-butyl-N-chlorocyanamide

  摘要：

  Treatment of aldoximes with N-tert-butyl-N-chlorocyanamide gave hydroximoyl chlorides in quantitative yields in less than a minute, which on dehydrohalogenation in the presence of triethylamine gave the corresponding nitrile oxides. The nitrile oxides underwent 1,3-dipolar addition to dipolarophiles and gave 2-isoxazolines in excellent yields under mild conditions. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2005.12.083
• 作为试剂：
  描述：

  二氯甲基醚 、 5,5'-dimethyl-3,3'-bipyrazole 在 氢氧化钾 、 叔丁胺氢溴酸盐 作用下， 以 二氯甲烷 为溶剂， 反应 12.0h， 以5%的产率得到(4E,5E,15E,16E)-2,7,13,18-tetramethyl-21,23-didehydro-9H,11H,20H,22H-10,21-dioxa-1,8,12,19-tetraazaporphyrin
  参考文献：
  名称：

  Lupo, B.; Tarrago, G., Bulletin de la Societe Chimique de France, 1984, vol. 2, # 11-12, p. 473 - 480

  摘要：

  DOI：

文献信息

• Factors relating to the formation of N-alkyl-B-halogenoborazines
  作者：I.M. Butcher、W. Gerrard

  DOI：10.1016/0022-1902(65)80443-2

  日期：1965.4

  The formation of N-alkyl-B-halogenoborazines from alkylammonium halide and boron trihalide (R = Me, Et, Prn, Pri, Bun, Bus, Oct.n but not But), entails the immediate formation of the tetrahalogenoborate, RNH3+BX4−, followed by the 1:1 complex, RNH2BX3, ill-defined further intermediates, and then the borazine according to the b.p. of the solvent used. Residues indicated further polymerisation; but were

  的形成ñ -烷基-乙从烷基卤化铵和三卤化硼（R =甲基，乙基，镨-halogenoborazines Ñ，镨我，卜Ñ，卜小号10月Ñ但不卜吨），需要的立即形成tetrahalogenoborate，RNH 3 + BX 4 - ，接着是1：1的复合物，RNH 2 BX 3，边界不清进一步的中间体，并且根据所使用的溶剂的沸点，则环硼氮烷。残留物表明进一步聚合。但没有进行化学分析以外的调查。叔丁基系统得到化合物Bu tNHBCl 2 ; 但不是硼嗪。在三乙胺存在，所述胺系统，除了卜吨之一，仍然得到环硼氮烷，而B吨得到borazocine（BU系统吨NBCl）4。
• Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix
  申请人：American Cyanamid Company

  公开号：US05929097A1

  公开（公告）日：1999-07-27

  The present invention relates to the discovery of novel, low molecular weight, non-peptide inhibitors of matrix metalloproteinases (e.g. gelatinases, stromelysins and collagenases) and TNF-.alpha. converting enzyme (TACE, tumor necrosis factor-.alpha. converting enzyme) which are useful for the treatment of diseases in which these enzymes are implicated such as arthritis, tumor growth and metastasis, angiogenesis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, proteinuria, aneurysmal aortic disease, degenerative cartilage loss following traumatic joint injury, demyelinating diseases of the nervous system, graft rejection, cachexia, anorexia, inflammation, fever, insulin resistance, septic shock, congestive heart failure, inflammatory disease of the central nervous system, inflammatory bowel disease, HIV infection, age related macular degeneration, diabetic retinopathy, proliferative vitreoretinopathy, retinopathy of prematurity, ocular inflammation, keratoconus, Sjogren's syndrome, myopia, ocular tumors, ocular angiogenesis/neovascularization. The TACE and MMP inhibiting ortho-sulfonamido aryl hydroxamic acids of the present invention are represented by the formula ##STR1## where the hydroxamic acid moiety and the sulfonamido moiety are bonded to adjacent carbons on group A.

  本发明涉及新发现的低分子量、非肽类基质金属蛋白酶（例如明胶酶、溶基质素和胶原酶）和肿瘤坏死因子α转化酶（TACE，肿瘤坏死因子α转化酶）的抑制剂，这些抑制剂用于治疗与这些酶相关的疾病，如关节炎、肿瘤生长和转移、血管生成、组织溃疡、异常伤口愈合、牙周病、骨病、蛋白尿、动脉瘤性主动脉疾病、关节创伤后的退行性软骨损失、神经系统脱髓鞘疾病、移植物排斥、恶病质、厌食、炎症、发热、胰岛素抵抗、感染性休克、充血性心力衰竭、中枢神经系统炎症性疾病、炎症性肠病、HIV感染、与年龄相关的黄斑变性、糖尿病视网膜病变、增生性玻璃体视网膜病变、早产儿视网膜病变、眼内炎症、圆锥角膜、干燥综合症、近视、眼内肿瘤、眼内血管生成/新生血管。本发明的TACE和MMP抑制的邻磺酰胺基芳基羟肟酸由下式表示：##STR1##，其中羟肟酸基团和磺酰胺基团通过相邻的碳原子与A组连接。
• Hydroquinone derivatives useful in the production of vitamin E
  申请人：Hoffmann-La Roche Inc.

  公开号：US04689427A1

  公开（公告）日：1987-08-25

  The present invention is directed to novel hydroquinone derivatives which are useful as intermediates for the manufacture of (R,R,R)-.alpha.-tocopherol (natural vitamin E) as well as of racemic .alpha.-tocopherol. The invention is also directed to a process for the preparation of the hydroquinone derivatives of the invention.

  本发明涉及一种新颖的对苯二酚衍生物，可用作(R,R,R)-α-生育酚（天然维生素E）以及混合α-生育酚的制造中间体。该发明还涉及一种制备本发明的对苯二酚衍生物的方法。
• Liquid crystal compounds with branched or cyclic end groups
  申请人：——

  公开号：US20040206933A1

  公开（公告）日：2004-10-21

  The use of a mesogenic compound having a terminal end chain comprising carbon, oxygen, or sulphur, which has at least one pendent C 1-4 alkyl, C 1-4 alkoxy or a cycloalkyl ring, arranged no more than 6 atoms from the end of the chain either decreasing the melting point, increasing the clearing point, increasing the speed of switching and/or increasing the tilt angle of a liquid crystal mixture. Examples of such compounds are of formula (I) where M is a mesogenic core group, and X and Y are terminal groups, provided that at least one group X or Y is a group of sub-formula (i) where Z 1 , Z 2 , R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , s, q, m and n are as defined in the specification. Novel compounds of formula (I) are also described and claimed. 1

  使用具有末端端基的向列相化合物，其包含碳、氧或硫，并且具有至少一个悬挂的C1-4烷基、C1-4烷氧基或环烷基，离链末端不超过6个原子，可以降低液晶混合物的熔点、提高清晰点、增加切换速度和/或增加倾斜角度。这些化合物的例子是公式(I)的化合物，其中M是向列相核心基团，X和Y是末端基团，但至少一个基团X或Y是子公式(i)的基团，其中Z1、Z2、R1、R2、R3、R4、R5、R6、R7、s、q、m和n如规范中所定义。还描述和声明了公式(I)的新化合物。
• Pyrazole derivatives
  申请人：Jones Howard Lyn

  公开号：US20060020012A1

  公开（公告）日：2006-01-26

  This invention relates to pyrazole derivatives of formula (I) or pharmaceutically acceptable salts, solvates or derivative thereofs, wherein R1 to R4 are defined in the description, and to processes for the preparation thereof, intermediates used in their preparation of, compositions containing them and the uses of such derivatives. The compounds of the present invention bind to the enzyme reverse transcriptase and are modulators, especially inhibitors thereof. As such the compounds of the present invention are useful in the treatment of a variety of disorders including those in which the inhibition of reverse transcriptase is implicated. Disorders of interest include those caused by Human Immunodificiency Virus (HIV) and genetically related retroviruses, such as Acquired Immune Deficiency Syndrome (AIDS).

  本发明涉及式（I）的吡唑衍生物或其药学上可接受的盐，溶剂或其衍生物，其中R1至R4在说明中定义，并涉及其制备过程，用于其制备的中间体，含有它们的组合物以及这些衍生物的用途。本发明的化合物与酶逆转录酶结合并调节其，特别是抑制其。因此，本发明的化合物在治疗各种疾病中有用，包括那些逆转录酶抑制剂有影响的疾病。感兴趣的疾病包括由人类免疫缺陷病毒（HIV）和遗传相关的逆转录病毒引起的疾病，例如获得性免疫缺陷综合症（AIDS）。